About us

NAL Pharma

NAL Pharma applies its proprietary Drug Delivery System (“DDS”) technologies to develop novel drug dosage forms and delivery systems, including:

• Bio-D3 Transdermal Patch DDS Technology 
• Bio-FX Fast-Onset Orally-Dissolving Film (ODF) DDS Technology
• Bio-CR Oral Controlled-Release Injectable DDS Technology
• Bio-NN Nanoparticle Controlled-Release Injectable DDS Technology
• Bio-MM Microsphere Extended-Release "Depot" Injectable DDS Technology

NAL utilizes its captive proprietary DDS technologies to:

• Convert patent-expiring blockbuster drugs into new DDS with improved features
• Develop products with enhanced patient compliance, safety, efficacy, and/or user convenience
• Improve quality attributes of products, such as stability, solubility, and delivery efficiency
• Extend product life cycles with new patent protections

By working with major pharmaceutical companies, NAL also utilizes its proprietary DDS technologies to:

• Advance the drug delivery systems of their new drug entities under development, in an effort to develop the best possible delivery systems at the earliest development stage
• Develop the new generation of their approved products by improving existing formulation

NAL is a privately owned corporation, headquartered in Hong Kong, working with international pharmaceutical development laboratories and manufacturing operations in the Asia, and Europe, in an effort to expedite the product development and commercialization of NAL’s products with international marketing partners in global markets.

About Us 

NAL Pharma is a specialty drug developer that develops novel dosage forms and proprietary drug delivery systems based on the Company’s captive Bio-D3, Bio-FX, Bio-CR, Bio-NN, and Bio-MM Drug Delivery System (“DDS”) technologies. For more detailed presentations and discussions, please contact us.

Headquartered in Hong Kong and with operation in the United States, NAL is developing non-infringing, proprietary and improved drug delivery systems that exhibit enhanced patient-compliance, safety, and/or efficacy compared with existing pharmaceutical products, and is also developing specially designed delivery systems to improve conventional dosage forms of new drugs undergoing Phase 2 clinical development that show significant first-pass metabolism side effects, poor solubility, and poor bioavailability.

As the US operation of NAL, Galaxy Bio, Inc. ("GBI") has established a captive R&D Laboratory in Princeton, New Jersey, USA for the development of afore-mentioned NAL's innovative and proprietary DDS products. Combining established product formulation and manufacturing development expertise, NAL has developed a number of non-infringing, proprietary and improved therapeutic products that incorporate patent-expiring drugs. NAL is working with major consumer healthcare companies to extend the life cycle of patent expiring drugs for the Rx-to-OTC switch. NAL is also working with major pharmaceutical companies to improve the formulations of their NCE drugs under development, in an effort to develop the most effective delivery systems based on NAL’s proprietary DDS Technologies.